Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022 06:59 ET | Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action – CABA
April 19, 2022 17:15 ET | The Rosen Law Firm PA
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or...
Retrophin Logo.jpg
Retrophin Provides Corporate Update and 2019 Outlook
January 07, 2019 07:00 ET | Retrophin, Inc.
SAN DIEGO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the...
Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain
August 20, 2018 08:19 ET | Taiwan Liposome Company, Ltd.
Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through  Weeks 12, 16, 20, and 24 TLC599 was well-tolerated with no...